Engene Therapeutics Inc. current report, 29 January 2024

Full document

Business Context and Reporting Period

enGene Holdings Inc. filed a Form 8-K dated January 29, 2024, under Item 2.02 to announce financial results for the fiscal year ended October 31, 2023. The filing identifies the registrant as a British Columbia corporation headquartered in Saint-Laurent, Quebec. The source text refers to enGene Holdings Inc.; it does not identify a separate entity named “Engene Therapeutics Inc.”

Financial Results and Key Metrics

The filing states that a related press release announced fiscal-year 2023 financial results, but the press release text and underlying financial figures are not included in the provided filing content.

  • Revenue: The filing text does not provide a clear value.
  • Net income or loss: The filing text does not provide a clear value.
  • Cash flow: The filing text does not provide a clear value.
  • Margins: The filing text does not provide a clear value.
  • Debt and liquidity: The filing text does not provide a clear value.
  • Other financial metrics: The filing text does not provide a clear value.

Changes Versus Prior Comparable Period

The filing does not provide comparative financial data or quantify changes from the prior fiscal year.

Guidance, Outlook, Risks, and Unusual Items

No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are included in the provided text. The financial information was furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except where expressly stated.

Investor Verification Items

  • Obtain and review Exhibit 99.1, the January 29, 2024 press release, for the actual fiscal-year 2023 financial results.
  • Verify revenue, operating expenses, net loss, cash and equivalents, cash usage, and financing obligations from the complete financial statements or earnings release.
  • Confirm any management guidance, expected cash runway, clinical-development milestones, and financing needs.
  • Note that the company’s common shares trade under “ENGN” and its warrants under “ENGNW” on Nasdaq.